Global Herpes Treatment Market by Type (Herpes zoster and Herpes simplex) and Geography (Asia, Europe, North America, and ROW) – Opportunities & Forecast, 2020-2024

LONDON–(BUSINESS WIRE)–#GlobalHerpesTreatmentMarket–The herpes treatment market is poised to grow by USD 677.02 million during 2020-2024 progressing at a CAGR of almost 4% during the forecast period.


Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Download Free Sample Report on COVID-19 Recovery Analysis

The report on the herpes treatment market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of herpes infection.

The herpes treatment market analysis includes the type segment and geography landscape. This study identifies the rising prevalence rate of shingles in the older population as one of the prime reasons driving the herpes treatment market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The Herpes Treatment Market covers the following areas:

Herpes Treatment Market Sizing

Herpes Treatment Market Forecast

Herpes Treatment Market Analysis

Companies Mentioned

  • Bausch Health Companies Inc.
  • Cipla Inc.
  • Eli Lilly and Co.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Maruho Co. Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.

     

Key Topics Covered:

Executive Summary

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 – 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type

  • Market segments
  • Comparison by Type
  • Herpes zoster – Market size and forecast 2019-2024
  • Herpes simplex – Market size and forecast 2019-2024
  • Market opportunity by Type

Customer Landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America – Market size and forecast 2019-2024
  • Europe – Market size and forecast 2019-2024
  • Asia – Market size and forecast 2019-2024
  • ROW – Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Competitive Scenario
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Bausch Health Companies Inc.
  • Cipla Inc.
  • Eli Lilly and Co.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Maruho Co. Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

     

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: media@technavio.com
Website: www.technavio.com/

Hologic Awarded U.S. Government Contract to Expand COVID-19 Test Production Capacity

$119 Million Contract Will Support Scale Up to 13 Million Tests Per Month for U.S. Market

MARLBOROUGH, Mass.–(BUSINESS WIRE)–#COVID19–Hologic, Inc. (Nasdaq: HOLX) announced today that it has been awarded a $119 million contract from the United States government to expand its production capacity for COVID-19 molecular tests. The contract will support capital and labor investments enabling Hologic to provide 13 million COVID-19 tests per month for the U.S. market by January of 2022.

Hologic’s Panther Fusion® SARS-CoV-2 Assay and Aptima® SARS-CoV-2 Assay received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration in March 2020 and May 2020, respectively. The tests run on the Company’s fully automated Panther Fusion® and Panther® systems, which provide initial results in approximately three hours and process more than 1,000 tests in 24 hours. More than 2,000 of these systems have been installed in clinical diagnostic laboratories around the world, including in all 50 U.S. states.

“Hologic has already made significant investments in our test production capacity, which have resulted in our contributing tens of millions of COVID tests to the United States supply,” said Kevin Thornal, president of the Diagnostic Solutions Division at Hologic. “Our manufacturing teams continue to innovate to increase our contribution, and we are very pleased to partner with the federal government to further our ability to meet the ongoing public health need.”

The Department of Defense Joint Rapid Acquisition Cell collaborated with the Department of the Air Force’s Acquisition COVID-19 Task Force and the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, to award the contract with BARDA funding. BARDA is also separately supporting development of Hologic’s COVID-19 assays.

About the Panther and Panther Fusion Systems

The Panther molecular diagnostics system is a best-in-class, fully automated, sample-to-result platform that can be used in low-, medium- or high-throughput laboratories. With a small footprint, adaptable workflow options and consolidated testing menu, it combines women’s health, sexually transmitted infections and viral testing, which can all be done simultaneously. In addition, patient samples can be loaded onto the Panther system as they arrive in the laboratory, a capability known as “random access” that improves efficiency and workflow. Overall, the instrument’s high throughput and quick turnaround time enable more patients to get results sooner.

The Panther Fusion system adds PCR (polymerase chain reaction) chemistry and provides an expanded in vitro diagnostics menu, as well as Open Access functionality to run laboratory developed tests. Together, the Panther and Panther Fusion systems now offer 16 FDA-cleared assays and 20 CE-marked assays that detect more than 20 pathogens.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Forward-Looking Statements

This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic’s Panther Fusion and Panther systems, and the Panther Fusion SARS-CoV-2 and Aptima SARS-CoV-2 Assays. There can be no assurance these products will receive full market authorization, achieve the benefits described herein, or be scaled up successfully. In addition, there can be no assurance that these products will be manufactured in adequate quantities to meet demand, be commercially successful, or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

Hologic, Aptima, Panther, Panther Fusion and The Science of Sure are registered trademarks of Hologic, Inc. in the United States and/or other countries.

SOURCE: Hologic, Inc.

Contacts

Investor Contact
Michael Watts

Vice President, Investor Relations and Corporate Communications

(858) 410-8588

michael.watts@hologic.com

Media Contact
Jane Mazur

Vice President, Divisional Communications

(585) 355-5978

jane.mazur@hologic.com

Icosavax Launches COVID-19 Vaccine Program with Preclinical Data and $16.5 Million in New Funding

Preclinical data published in Cell show the company’s COVID-19 vaccine candidate induces high neutralizing antibody titers after a single administration

SEATTLE–(BUSINESS WIRE)–#COVID19Icosavax, Inc. today announced the launch of the company’s COVID-19 vaccine program with preclinical data on the company’s VLP vaccine candidate, IVX-411, which comprises a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain (RBD) in a highly immunogenic array. Icosavax also announced that the Bill & Melinda Gates Foundation has provided a $10 million grant to support the company’s COVID-19 vaccine program through the first in human Phase 1 clinical trial in young and older adults, expected to initiate in mid-2021. In addition, Icosavax received $6.5 million from Open Philanthropy to support development of the company’s vaccine platform technology and COVID-19 vaccine candidate. The company is currently advancing the necessary studies to support regulatory filings and has initiated GMP manufacturing. To enable rapid progress of the company’s COVID-19 vaccine candidate to the clinic, Amgen has agreed to manufacture a key intermediate for initial clinical studies.

“This is truly a great example of the scientific community coming together in a time of exceptional need to fight this pandemic. We are grateful to the Bill & Melinda Gates Foundation and Open Philanthropy for their financial support and to Amgen for the supply of a key intermediate for manufacturing,” said Adam Simpson, Chief Executive Officer of Icosavax. “The team at Icosavax is dedicated to advancing vaccines against severe life-threatening respiratory diseases to protect our most at-risk populations. Because VLP vaccines have the potential to induce high-neutralizing antibody titers, our COVID-19 VLP vaccine candidate could be especially important for older adults with age-related declines in immunity.”

Developed by scientists at the University of Washington School of Medicine using structure-based vaccine design techniques invented at the Institute for Protein Design (IPD) at the UW Medicine, IVX-411, the lead vaccine candidate for COVID-19, is a self-assembling protein nanoparticle that displays 60 copies of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain in a highly immunogenic array. Preclinical data from UW researchers and their collaborators show IVX-411 induces high neutralizing antibody titers in mice after a single administration and further improvement after a second administration (Cell 2020). Titers after the second administration were ten-fold higher than those seen with the soluble SARS-CoV-2 spike protein that forms the basis of many other vaccine candidates. The data also show a strong B-cell response after immunization, critical for immune memory and a durable vaccine effect, with antibodies that target multiple distinct epitopes on the RBD, suggesting potential protection from escape mutations.

“These data highlight that while our VLP-based SARS-CoV-2 vaccine may not be first to market, it has the potential to be a best-in-class vaccine that safely delivers potent and durable immune protection,” said Icosavax co-founder Neil King, Ph.D. Dr. King is also inventor of the computationally designed VLP technology at the Institute for Protein Design, and assistant professor of biochemistry at the UW School of Medicine. “This technology is designed to drive higher neutralizing antibody titers than soluble protein approaches and to create safe, stable, and effective VLP vaccines with simple and scalable manufacturing.”

“It’s clear that we will need a variety of vaccine approaches to effectively fight this novel coronavirus,” said Jean-Paul Prieels, Ph.D., former Senior Vice President of Research and Development at GSK Vaccines and member of the scientific advisory board of Icosavax. “That’s why it’s important to advance not just the fastest but the best vaccine technologies that can deliver safe, effective, and durable protection.”

VLPs enable high-density, multivalent display of antigens in a manner that closely resembles viruses, with an important difference. VLPs contain no genetic material, so they are non-infectious and can provide a safer alternative to live-attenuated or inactivated vaccines. The high yield and stability of the protein components and assembled nanoparticles suggest that manufacture of the nanoparticle vaccines will be highly scalable.

Icosavax has a worldwide license with an exclusive option for IVX-411 in North America and Europe from the University of Washington.

About Icosavax

Icosavax is focused on developing safe and effective vaccines against infectious diseases that cause severe, life-threatening respiratory illnesses. In addition to the COVID-19 vaccine candidate, Icosavax is also advancing IVX-121 into clinical trials as a potential vaccine for respiratory syncytial virus (RSV) for older adults. The company was founded on breakthrough computationally-designed virus like particle technology developed at the Institute for Protein Design and exclusively licensed from the University of Washington. Icosavax is located in Seattle. For more information, please visit www.icosavax.com.

Contacts

Media Contact:

Jessica Yingling, Ph.D.

Little Dog Communications Inc.
jessica@litldog.com
+1.858.344.8091

Biodesix Announces Closing of Initial Public Offering

BOULDER, Colo.–(BUSINESS WIRE)–Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix”) today announced the closing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $18.00 per share. The gross proceeds to Biodesix, before deducting underwriting discounts and commissions, were approximately $72.0 million. The shares began trading on The Nasdaq Global Market on October 28, 2020, under the symbol “BDSX.”

Morgan Stanley and William Blair acted as lead book-running managers for the offering. Canaccord Genuity acted as lead manager and BTIG acted as co-manager for the offering.

The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from: Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, or by email at prospectus@morganstanley.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687 or by email at prospectus@williamblair.com.

A registration statement relating to the shares being sold in this offering has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

Contacts

Jeremy Feffer

jeremy@lifesciadvisors.com

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CHICAGO–(BUSINESS WIRE)–Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on October 28, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 36,250 share(s) of its common stock to 15 new employee(s) under Xeris’ Inducement Equity Plan.

Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual’s entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The non-qualified stock options will vest over a period of four years, either 25% on the first anniversary of the grant with the remaining 75% vesting in thirty-six equal monthly installments thereafter, or 36% on 18 months after the grant date with the remaining 64% vesting in ten equal quarterly installments thereafter, and are subject to the employees’ continued employment with Xeris or one of its subsidiaries. The non-qualified stock options are subject to the terms and conditions of Xeris’ Inducement Equity Plan and forms of award agreements covering the grants.

About Xeris Pharmaceuticals, Inc.

Xeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.

With a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke®. Its proprietary XeriSol™ and XeriJect™ formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris’ technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.

Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on Twitter, LinkedIn or Instagram.

Contacts

Investor Contact
Allison Wey

Senior Vice President, Investor Relations and Corporate Communications

awey@xerispharma.com
312-736-1237

Sproutly Announces Financial Results for the Second Quarter Of 2021

NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES

VANCOUVER, British Columbia–(BUSINESS WIRE)–Sproutly Canada, Inc. (CSE: SPR) (OTCQB: SRUTF) (FRA: 38G) (“Sproutly” or the “Company”) today announced the Company’s financial results for the second quarter ended August 31, 2020.

“While we saw an increase in our flower revenue in this quarter as compared to Q1, the big news came subsequent to the end of the quarter when we received our Cannabis 2.0 sales license,” said Dr. Arup Sen, Chief Executive Officer of Sproutly. “This is the milestone we needed to achieve in order to sell differentiated cannabis and hemp products that use the natural water soluble and oil ingredients produced by our APP technology in Canada.”

Highlights for the Second Quarter Ended August 31, 2020

  • THR entered into a cannabis supply agreement with the province of British Columbia through the British Columbia Liquor Distribution Branch as well as completing initial sales into the province. This is the 5th province in Canada to carry the Company’s CALIBER branded indoor-grown dried flower products.
  • The Company reorganized their Board of Directors. Michael Bellas, Gregg Orr and Justin Kates departed, with Craig Loverock and Paul Marcellino joining the Board. In addition, Con Constandis was named Chair of the Audit Committee with Dr. Arup Sen taking over as Board Chairman.
  • The Company amended the interest clause on its previously issued convertible debentures such that the Company can now settle the interest owing through the issuance of common shares or cash, subject to the prior written approval of Debenture holders holding more than 20% of the outstanding Debentures.
  • The Company secured a private loan of $855,000 from Infusion Biosciences Inc., a related party of the Company. The Loan carries an interest rate of 15% per annum accruing and compounding monthly, payable on maturity on or before October 24, 2020.
  • The Company completed a non-brokered private placement of 1,500,000 units of the Company at a price of $0.07 per Equity Unit to raise gross proceeds of $105,000. Each Equity Unit consists of one Common Share and one Warrant, with each Warrant entitling the holder to acquire one Warrant Share at an exercise price equal to $0.08 for a period of two years from date of issuance.
  • The Company completed a settlement of outstanding current debt of the Company in the amount of $180,000 with an arm’s length creditor. In settlement of the Debt, the Company has issued 1,800,000 Common Shares (the “Settlement Shares”) at a price of $0.10 per Settlement Share.

Subsequent Events

  • The Company’s wholly-owned subsidiary, Toronto Herbal Remedies Inc., (“THR”), a licensed producer and processor under the Cannabis Act, has received its cannabis extract sales license from Health Canada (the “Sales License”). THR is now authorized to manufacture and sell Cannabis 2.0 products directly to provincial distributors and other authorized Canadian retail supply channels. THR’s ability to sell Cannabis 2.0 products allows it to utilize its licensed APP technology and offer the Company’s strain specific cannabis extracts, edible and beverage products in Canada through its existing provincial sales relationships.
  • The Company amended maturity date of its previously issued convertible debentures from October 24, 2020 to April 24, 2021 and reduced the conversion price from $0.105 to $0.06 per share.
  • The Company and Infusion Biosciences Inc. (“Infusion”) extended the maturity dates of both the $1 million private loan issued by Infusion to the Company on January 28, 2020 and the $855,000 private loan issued by Infusion to the Company on August 27, 2020 by six months to April 24, 2021.
  • The Company settled an aggregate of $182,340 of payroll indebtedness owed to certain current and former employees for past services rendered through the issuance of 2,604,867 common shares at a deemed issuance price of $0.07 per share.
  • The Company settled an aggregate of approximately $69,300 of indebtedness owed to one arms-length creditor for past services rendered through the issuance of 1,386,000 common shares at a deemed issuance price of $0.05 per share.

Consolidated Financial Statements and Management’s Discussion and Analysis

The Company’s unaudited consolidated interim financial statements and accompanying notes at and for the period ended August 31, 2020, and the Company’s Management’s Discussion and Analysis for the period ended August 31, 2020 are available under the Company’s profile on SEDAR at www.sedar.com.

About Sproutly Canada, Inc.

Sproutly’s core objective is to become the leading supplier of unique ingredients and customized formulations to the cannabis beverage and edibles market. Our water-soluble Infuz2O and BioNatural Oils will deliver unique brands to international markets that are striving to produce differentiated consumer products. Sproutly’s business focus is to execute on partnerships with local and globally established consumer companies to leverage their existing customer bases, further expand brand loyalty, assist with marketing, and support distribution networks to deliver the benefits of the APP technology with speed and efficiency worldwide.

For more information on Sproutly, please visit www.sproutly.ca.

Forward-Looking Statements

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or future performance and reflect the expectations or believes regarding future events of management of Sproutly Canada. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements, referred to herein as “forward-looking statements”, are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management’s expectations and intentions with respect to, among other things, the date of trading of the Sproutly Shares on the CSE and final regulatory approvals. These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, and other factors, many of which are beyond the control of Sproutly Canada. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

Contacts

Dr. Arup Sen, Chief Executive Officer of Sproutly Canada, Inc.

Email: investorrelations@sproutly.ca

5th LifeSciences BC Investor Summit Attracts International Interest

VANCOUVER, British Columbia–(BUSINESS WIRE)–#LSBCinvestLifeSciences BC, a non-profit, industry association which supports the life sciences sector of British Columbia, and Lumira Ventures, a leading North American healthcare venture capital firm, will host the 5th Annual LifeSciences BC’s Investor Summit in Vancouver, B.C., virtually on November 2nd and 3rd, 2020.

With keynotes given by Mr. Daniel Hétu, Managing Director of Lumira Ventures and Mr. Peter Greenleaf, CEO of Aurinia Pharmaceuticals, the event brings together prominent industry stakeholders from the healthcare innovation ecosystem for company pitching and fostering of strategic partnerships with international investors. At this year’s Annual Investor Summit, companies from across the life sciences sector are pitching from the following areas: Digital Health, Medical Devices, Medical Technology, Diagnostics, and Biotechnology. International investors are attending from Japan, France, China, Hong Kong and the United States.

This premier event will profile more than 30 digital health, therapeutics, and medical technology entrepreneurs from British Columbia’s highly acclaimed life sciences sector. Each of the selected companies will have the opportunity to present their company’s story and receive feedback and engagement from a wide range of investor stakeholders including, angel investors, venture capitalists, corporate ventures and funding foundations. The event also includes ‘Reverse Pitches’ from global pharma companies including Amgen, Johnson & Johnson and Takeda about the innovations they are interested in, plus, presentations from the Trade Commissioner Service of Global Affairs Canada about the unique opportunities that exists for British Columbia’s life sciences companies globally.

“Our Annual Investor Summit provides BC companies an important platform and opportunity to make connections to advance their therapeutics and technologies to an audience of seasoned investors. At LifeSciences BC, we recognize the importance of building bridges to catalyze connections that drive commercialization, which can be extremely difficult for any start up or mid stage company. Events such as this are critical to growth and overall awareness of the importance of the ecosystem in BC’s economic engine,” says Wendy Hurlburt, President and CEO, LifeSciences BC.

The Honourable Navdeep Bains, Minister of Innovation, Science and Industry says, “The life sciences sector in British Columbia and Canada has a proud history of ingenuity, with tremendous potential as a driver for investments, innovations, and well-paying jobs. COVID-19 has shone a light on the critical importance of this sector and our government has been there to support Canadian companies working around the clock to find solutions. We will continue working with the life sciences sector in British Columbia and across the country to drive innovation and discovery and strengthen Canadian leadership in this global industry.”

Event Details

Program: Monday, November 2, 2020

  • 9.00AM: Welcome and Opening Remarks – Wendy Hurlburt, President & CEO, LifeSciences BC and Daniel Hétu, Managing Director, Lumira Ventures
  • 9.15AM: Keynote Presentation: Peter Greenleaf, CEO, Aurinia Pharmaceuticals
  • 9.15AM – 12.00PM: Session – Therapeutics
  • 1.00PM – 2.00PM: Session – Mixed Sectors
  • 2.00PM – 3.00PM: Global Investment Presentation
  • 3.00PM – 4.00PM: BC Success Stories – Chinook Therapeutics
  • 4.00PM – 4.15PM: Closing Remarks

Program: Tuesday, November 3, 2020

  • 9.00AM: Welcome Remarks
  • 9.30AM – Noon: Morning Session – Medical Devices
  • 1.00PM – 2.00PM: Session – Digital Health
  • 2.00PM – 3.00PM: Pharma Reverse Pitch
  • 3.00PM – 4.00PM: Panel Discussion
  • 4.00PM – 4.15PM: Closing Remarks by LSBC & Lumira Ventures

About LifeSciences BC

LifeSciences BC is a non-profit, industry association which represents the life science community of British Columbia. The Association undertakes numerous initiatives including; local, national and international partnerships that help facilitate investment and global partnering opportunities while nurturing economic development in B.C. www.lifesciencesbc.ca

Contacts

For Inquiries about the Investor Summit and LifeSciences BC, please contact:

Susan Ogilvie, Senior Manager, Communications & External Affairs

604-669-9909 – EXT 106

604-218-5188

sogilvie@lifesciencesbc.ca

For Media Inquiries, please contact:
Kamran Shaikh

778-846-5406

kshaikh@prassociates.com

Humanigen Announces First Patient Dosed at MedStar Washington Hospital Center in Phase 3 Clinical Study of Lenzilumab in COVID-19

  • New study site actively enrolling eligible hospitalized patients with COVID-19 in clinical trial in Washington, D.C.

BURLINGAME, Calif.–(BUSINESS WIRE)–Humanigen, Inc. (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with lenzilumab, today announced that MedStar Washington Hospital Center in Washington, D.C. treated its first COVID-19 patient with lenzilumab. The primary goal of this Phase 3 randomized, double-blind, multicenter, placebo-controlled clinical trial is to determine if lenzilumab can help hospitalized patients with COVID-19 recover faster. As many as 89% of hospitalized patients with COVID-19 are at risk of a complication called cytokine storm, a harmful inflammation that has been the leading cause of COVID-19 death. MedStar Washington Hospital Center is one of 18 sites in the U.S. approved to enroll eligible patients to study lenzilumab, designed specifically to stop this storm. Eligible patients can participate in this trial while also receiving other standard-of-care therapies as recommended by their treating physician.

“Given the growing number of cases in the D.C. area seen in the past few weeks, we were particularly motivated to ensure our Phase 3 study was enrolling and accessible,” said Cameron Durrant, MD, MBA, chief executive officer of Humanigen. “We have been impressed with the hospital leadership and trial investigators at MedStar Washington, and worked together with speed and efficiency to get this trial location ready to enroll patients.”

For more information on participating in the Phase 3 COVID-19 trial of lenzilumab, please visit StopStorm.com, and talk to your doctor to see if you may be eligible to participate.

More details on Humanigen’s programs in COVID-19 can be found on the Company’s website at www.humanigen.com under the COVID-19 tab, and details of the U.S. Phase 3 potential registration study can be found at clinicaltrials.gov using Identifier NCT04351152.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The company’s immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab™ as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit www.humanigen.com.

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as “will,” “expect,” “intend,” “plan,” “potential,” “possible,” “goals,” “accelerate,” “continue,” and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations for the Phase 3 study and the potential future development of lenzilumab, our pathway to our intended submission for, and potential receipt of, an Emergency Use Authorization and potential subsequent BLA from FDA, and statements regarding the potential for lenzilumab to be used to prevent or treat GvHD and, as sequenced therapy with Kite’s Yescarta, in CAR-T therapies. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability; our dependence on partners to further the development of our product candidates; the costs and the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the “Risk Factors” sections and elsewhere in the Company’s periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

Contacts

Media
Cammy Duong

Westwicke, an ICR company

cammy.duong@westwicke.com
203-682-8380

Assessment of COVID-19’s Effect on Anatomic Pathology Track and Trace Solution Market 2020-2024 | Growing Use of Automated Systems to Augment Growth | Technavio

LONDON–(BUSINESS WIRE)–#AnatomicPathologyTrackandTraceSolutionsMarket–The anatomic pathology track and trace solution market is poised to grow by USD 271.72 million during 2020-2024 progressing at a CAGR of almost 10% during the forecast period.


Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Download Free Sample Report on COVID-19 Recovery Analysis

The report on the anatomic pathology track and trace solution market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing use of automated systems.

The anatomic pathology track and trace solution market analysis includes the technology segment and geography landscape. This study identifies the digitization of healthcare as one of the prime reasons driving the anatomic pathology track and trace solution market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The Anatomic Pathology Track and Trace Solution market covers the following areas:

Anatomic Pathology Track and Trace solution Market Sizing

Anatomic Pathology Track and Trace solution Market Forecast

Anatomic Pathology Track and Trace solution Market Analysis

Companies Mentioned

  • Agilent Technologies Inc.
  • AP Easy Software Solutions
  • Cerebrum Corp.
  • Danaher Corp.
  • F. Hoffmann-La Roche Ltd.
  • General Data Co. Inc.
  • LigoLab LLC
  • PHC Holdings Corp.
  • Primera Technology Inc.
  • Zebra Technologies Corp.

     

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
  • Value chain analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
  • Market outlook

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TECHNOLOGY

  • Market segmentation by technology
  • Comparison by technology
  • Barcode – Market size and forecast 2019-2024
  • RFID – Market size and forecast 2019-2024
  • Market opportunity by technology

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America – Market size and forecast 2019-2024
  • Europe – Market size and forecast 2019-2024
  • Asia – Market size and forecast 2019-2024
  • ROW – Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Digitization of healthcare
  • Decline in number of pathologists
  • Increasing healthcare expenditure

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Agilent Technologies Inc.
  • AP Easy Software Solutions
  • Cerebrum Corp.
  • Danaher Corp.
  • F. Hoffmann-La Roche Ltd.
  • General Data Co. Inc.
  • LigoLab LLC
  • PHC Holdings Corp.
  • Primera Technology Inc.
  • Zebra Technologies Corp.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: media@technavio.com
Website: www.technavio.com/

Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn

Pfizer Announces Record Date for the Proposed Transaction

HERTFORDSHIRE, England & PITTSBURGH & NEW YORK–(BUSINESS WIRE)–Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Federal Trade Commission (the “FTC”) accepted a proposed consent order, which concludes the FTC’s review of the proposed combination of Mylan and Pfizer’s Upjohn Business. The parties have now obtained all required antitrust clearances for the proposed transaction.

The combination will be effected through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. will be spun off to Pfizer’s stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan. Pfizer has set the close of business on November 13, 2020 as the record date for this proposed spin-off. The combination is expected to close on November 16, 2020, at which time the combined company will be renamed Viatris Inc.

Future Viatris Executive Chairman and current Mylan Executive Chairman, Robert J. Coury, said, “Today’s approval represents the final significant milestone towards the creation of Viatris and the realization of Mylan’s and Upjohn’s shared vision for the future of healthcare. We are focused on taking the final steps to close our transaction and look forward to unlocking the true value of our combined company for shareholders, employees, partners, patients and customers around the world. I would like to thank our current and future colleagues, as well as Pfizer’s leadership team, who have worked tirelessly to help pave the way for Viatris’ first day – November 16.”

Pfizer Chairman and Chief Executive Officer Dr. Albert Bourla said, “We are pleased to have received all necessary regulatory approvals for the proposed combination of Mylan and Upjohn. We expect the new company, Viatris, will deliver value to shareholders and the global healthcare community. For Pfizer, this transaction furthers our sharpened focus on innovative medicines and breakthroughs that change patients’ lives.”

Upon completion of the combination, Pfizer stockholders as of the record date will own 57% of the outstanding shares of Viatris common stock, and Mylan shareholders will own 43% of the outstanding shares of Viatris common stock, in each case on a fully diluted, as-converted and as-exercised basis. The number of shares of Viatris common stock that each holder of Pfizer common stock as of the record date will receive will be determined based on the number of shares of Pfizer common stock outstanding as of the record date and the number of Mylan ordinary shares outstanding as of the trading day immediately prior to the closing date, in each case calculated on a fully diluted, as-converted and as-exercised basis.

Pfizer stockholders do not need to pay any consideration, exchange or surrender their Pfizer common stock or take any other action to receive Viatris common stock in the distribution, other than to hold Pfizer common stock as of the record date.

Details of “when-issued” and “ex-distribution” trading, if any, in connection with the combination will be announced at a later time.

The transaction remains subject to the satisfaction of other customary closing conditions. The two businesses will continue to operate as independent, separate organizations until close. For more information, visit championforglobalhealth.com.

About Mylan

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what’s right, not what’s easy; and impact the future through passionate global leadership. We offer a portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which approximately 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world’s largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.com. We routinely post information that may be important to investors on our website at investor.mylan.com.

About Upjohn

With over 130 years of experience in improving patient lives, Pfizer Upjohn seeks to leverage our portfolio, global experience and expertise to become the trusted partner of choice for all stakeholders committed to improving patient health. We focus on relieving the burden of noncommunicable diseases with trusted, quality medicines for every patient, everywhere, with the goal of treating 225 million new patients by 2025. Upjohn brings together 20 of the industry’s most trusted brands — products such as Lipitor®, Norvasc®, Lyrica® and Viagra® — with world-class medical, manufacturing and commercial expertise in more than 120 countries. Upjohn’s network of approximately 11,500 colleagues works together to be fast, focused and flexible to ensure that patients around the world access the healthcare they need.

About Pfizer: Breakthroughs That Change Patients’ Lives®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Forward-Looking Statements

This communication contains “forward-looking statements.” Such forward-looking statements may include, without limitation, statements about the proposed combination of Upjohn Inc. (“Newco”) and Mylan N.V. (“Mylan”), which will immediately follow the proposed separation of the Upjohn Business (the “Upjohn Business”) from Pfizer Inc. (“Pfizer”) (the “proposed transaction”), the expected timetable for completing the proposed transaction, the benefits and synergies of the proposed transaction, future opportunities for the combined company and products and any other statements regarding Pfizer’s, Mylan’s, the Upjohn Business’s or the combined company’s future operations, financial or operating results, capital allocation, dividend policy, debt ratio, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competitions, and other expectations and targets for future periods. Forward looking statements may often be identified by the use of words such as “will”, “may”, “could”, “should”, “would”, “project”, “believe”, “anticipate”, “expect”, “plan”, “estimate”, “forecast”, “potential”, “pipeline”, “intend”, “continue”, “target”, “seek” and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: ongoing challenges and uncertainties posed by the COVID-19 pandemic for businesses and governments around the world; the parties’ ability to meet expectations regarding the timing, completion and accounting and tax treatments of the proposed transaction; changes in relevant tax and other laws; the parties’ ability to consummate the proposed transaction; the conditions to the completion of the proposed transaction not being satisfied or waived on the anticipated timeframe or at all; inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements and the providing of estimates of financial measures, in accordance with accounting principles generally accepted in the United States and related standards or on an adjusted basis; the integration of Mylan and the Upjohn Business being more difficult, time consuming or costly than expected; Mylan’s, the Upjohn Business’s and the combined company’s failure to achieve expected or targeted future financial and operating performance and results; the possibility that the combined company may be unable to achieve expected benefits, synergies and operating efficiencies in connection with the proposed transaction within the expected time frames or at all or to successfully integrate Mylan and the Upjohn Business; customer loss and business disruption being greater than expected following the proposed transaction; the retention of key employees being more difficult following the proposed transaction; Mylan’s, the Upjohn Business’s or the combined company’s liquidity, capital resources and ability to obtain financing; any regulatory, legal or other impediments to Mylan’s, the Upjohn Business’s or the combined company’s ability to bring new products to market, including but not limited to where Mylan, the Upjohn Business or the combined company uses its business judgment and decides to manufacture, market and/or sell products, directly or through third parties, notwithstanding the fact that allegations of patent infringement(s) have not been finally resolved by the courts (i.e., an “at-risk launch”); success of clinical trials and Mylan’s, the Upjohn Business’s or the combined company’s ability to execute on new product opportunities; any changes in or difficulties with Mylan’s, the Upjohn Business’s or the combined company’s manufacturing facilities, including with respect to remediation and restructuring activities, supply chain or inventory or the ability to meet anticipated demand; the scope, timing and outcome of any ongoing legal proceedings, including government investigations, and the impact of any such proceedings on Mylan’s, the Upjohn Business’s or the combined company’s consolidated financial condition, results of operations and/or cash flows; Mylan’s, the Upjohn Business’s and the combined company’s ability to protect their respective intellectual property and preserve their respective intellectual property rights; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel; changes in third-party relationships; actions and decisions of healthcare and pharmaceutical regulators; the impacts of competition; changes in the economic and financial conditions of the Upjohn Business or the business of Mylan or the combined company; the impact of outbreaks, epidemics or pandemics, such as the COVID-19 pandemic; uncertainties regarding future demand, pricing and reimbursement for Mylan’s, the Upjohn Business’s or the combined company’s products; and uncertainties and matters beyond the control of management and other factors described under “Risk Factors” in each of Pfizer’s, Newco’s and Mylan’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission (“SEC”). These risks, as well as other risks associated with Mylan, the Upjohn Business, the combined company and the proposed transaction are also more fully discussed in the Registration Statement on Form S-4, as amended, which includes a proxy statement/prospectus (as amended, the “Form S-4”), which was filed by Newco with the SEC on October 25, 2019 and declared effective by the SEC on February 13, 2020, the Registration Statement on Form 10, which includes an information statement (the “Form 10”), which was filed by Newco with the SEC on June 12, 2020 and declared effective by the SEC on June 30, 2020, a final information statement furnished with the Current Report on Form 8-K filed by Newco with the SEC on August 6, 2020 (the “Final Information Statement”), a definitive proxy statement, which was filed by Mylan with the SEC on February 13, 2020 (the “Proxy Statement”), and a prospectus, which was filed by Newco with the SEC on February 13, 2020 (the “Prospectus”). You can access Pfizer’s, Mylan’s and Newco’s filings with the SEC through the SEC website at www.sec.gov or through Pfizer’s or Mylan’s website, as applicable, and Pfizer and Mylan strongly encourage you to do so. Except as required by applicable law, Pfizer, Mylan and Newco undertake no obligation to update any statements herein for revisions or changes after this communication is made.

ADDITIONAL INFORMATION AND WHERE TO FIND IT

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. In connection with the proposed transaction, Newco and Mylan have filed certain materials with the SEC, including, among other materials, the Form S-4, Form 10 and Prospectus filed by Newco and the Proxy Statement filed by Mylan. The Form S-4 was declared effective on February 13, 2020 and the Proxy Statement and the Prospectus were first mailed to shareholders of Mylan on or about February 14, 2020 to seek approval of the proposed transaction. The proposed transaction was approved by Mylan’s shareholders on June 30, 2020. The Form 10 was declared effective on June 30, 2020. Newco made available the Final Information Statement on or about August 6, 2020. Newco and Mylan intend to file additional relevant materials with the SEC in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MYLAN, NEWCO AND THE PROPOSED TRANSACTION. The documents relating to the proposed transaction (when they are available) can be obtained free of charge from the SEC’s website at www.sec.gov. These documents (when they are available) can also be obtained free of charge from Mylan, upon written request to Mylan or by contacting Mylan at (724) 514-1813 or investor.relations@mylan.com or from Pfizer on Pfizer’s internet website at https://investors.Pfizer.com/financials/sec-filings/default.aspx or by contacting Pfizer’s Investor Relations Department at (212) 733-2323, as applicable.

Contacts

Mylan Media Contact:

Jennifer Mauer

724-514-1968

Jennifer.Mauer@Mylan.com

Mylan Investor Contact:

Melissa Trombetta

724-514-1813

Melissa.Trombetta@Mylan.com

Pfizer Media Contact:

Amy Rose

212-733-7410

Amy.Rose@Pfizer.com

Pfizer Investor Contact:

Charles Triano

212-733-3901

Charles.E.Triano@Pfizer.com